Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Washington University School of Medicine |
---|---|
Information provided by: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00492375 |
Primary Objectives
Secondary Objectives
Condition | Intervention | Phase |
---|---|---|
Metastatic Breast Cancer |
Drug: cetuximab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Active Control, Single Group Assignment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 06-0220 |
Study First Received: | June 25, 2007 |
Last Updated: | October 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00492375 |
Health Authority: | United States: Food and Drug Administration |
Skin Diseases Cetuximab Breast Neoplasms Carboplatin Breast Diseases |
Neoplasms Neoplasms by Site Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |